KoBioLabs, Inc (KOSDAQ:348150)
South Korea · Delayed Price · Currency is KRW 5,900.00
+200.00 (3.51%)
At close: Jan 28, 2026
KoBioLabs Revenue
KoBioLabs had revenue of 19.26B KRW in the quarter ending September 30, 2025, with 13.88% growth. This brings the company's revenue in the last twelve months to 71.83B, up 17.19% year-over-year. In the year 2024, KoBioLabs had annual revenue of 68.36B with 106.28% growth.
Revenue (ttm)
71.83B
Revenue Growth
+17.19%
P/S Ratio
1.64
Revenue / Employee
n/a
Employees
n/a
Market Cap
117.87B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 68.36B | 35.22B | 106.28% |
| Dec 31, 2023 | 33.14B | 21.53B | 185.54% |
| Dec 31, 2022 | 11.61B | 8.71B | 301.12% |
| Dec 31, 2021 | 2.89B | -1.70B | -36.98% |
| Dec 31, 2020 | 4.59B | 4.01B | 696.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 132.76B |
| Cell Biotech | 50.65B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 21.87B |
| BIO-FD&C | 18.82B |
| TegoScience | 6.15B |
| NovMetaPharma | 1.30B |
| Progen | 450.00M |